Francesca Rossetti
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
A viable human lung cancer tissue collection (LCTC) to accelerate translational research.
Journal: Cancer treatment and research communications
Published: July 21, 2025
Lung Cancer Screening: The European Perspective.
Journal: Thoracic surgery clinics
Published: October 08, 2023
Prolonged air leak after robotic lung resection: a narrative review.
Journal: Journal of thoracic disease
Published: June 17, 2022
Lung cancer screening: who pays? Who receives? The European perspectives.
Journal: Translational lung cancer research
Published: June 24, 2021
Venoarterial Extracorporeal Membrane Oxygenation Support in Lung Cancer Resection.
Journal: The Annals of thoracic surgery
Published: March 03, 2021
Distinguishing multiple lung primaries from intra-pulmonary metastases and treatment implications.
Journal: Expert review of anticancer therapy
Published: September 11, 2020
The role of EBUS-TBNA in lung cancer restaging and mutation analysis.
Journal: Mediastinum (Hong Kong, China)
Published: May 13, 2020
Isolated tension pneumoperitoneum following endobronchial ultrasound-guided transbronchial needle aspiration complicated by cardiac peri-arrest: A case report.
Journal: Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace
Published: September 25, 2018
18F-FAZA PET/CT in the Preoperative Evaluation of NSCLC: Comparison with 18F-FDG and Immunohistochemistry.
Journal: Current radiopharmaceuticals
Published: September 07, 2017
Concomitant Lung Cancer and Gastrointestinal Stromal Tumor: First Report of Hypoxia Imaging With 18F-FAZA PET/CT.
Journal: Clinical nuclear medicine
Published: May 20, 2017
First Evaluation of PET-Based Human Biodistribution and Dosimetry of 18F-FAZA, a Tracer for Imaging Tumor Hypoxia.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: November 02, 2016
Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Journal: Antiviral therapy
Published: January 31, 2013
Last Updated: 09/26/2026